AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Homogentisate 1,2-dioxygenase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q93099

UPID:

HGD_HUMAN

Alternative names:

Homogentisate oxygenase; Homogentisic acid oxidase; Homogentisicase

Alternative UPACC:

Q93099; A8K417; B2R8Z0

Background:

Homogentisate 1,2-dioxygenase, also known as Homogentisate oxygenase, plays a crucial role in the breakdown of amino acids phenylalanine and tyrosine. It catalyzes the conversion of homogentisate to maleylacetoacetate, a key step in the catabolic pathway. This enzyme's malfunction is directly linked to Alkaptonuria, a metabolic disorder characterized by urine that darkens upon standing and severe arthritis.

Therapeutic significance:

The direct association of Homogentisate 1,2-dioxygenase with Alkaptonuria highlights its therapeutic significance. Targeting this enzyme could lead to innovative treatments for Alkaptonuria, focusing on enzyme replacement or enhancement to correct the metabolic pathway.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.